Most of the original shareholders have seen their holdings diluted to almost nothing and it seems unlikely they will bother to attend the meeting this week.
The faltering debacle over the past nine months has dashed any hope I had of an early recovery in the share price despite the new Ironbridge connection and all the latter’s experience of corporate manoeuvring and success in the past. It has taken nine months and still counting for them to understand what information the regulators require to re-comply with the ASX Listing Rules. Have they no previous experience with such situations? They claim not to be novices.
Meanwhile, amidst all the excitement in the battery related resources sector, all that has been achieved for NAV is the acquisition of an uninspiring gold prospect which has no relevance to the new field of pharmaceuticals towards which the future of the company has been directed. All very disappointing and risking a dilutary waste of what little money the company still had.
We wait to see if some progress may at last be achieved.